Loading...
Loading...
VRDN| Name | Value |
|---|---|
| Revenues | 0.1M |
| Cost of Revenue | 5.8M |
| Gross Profit | -5.7M |
| Operating Expense | 72.3M |
| Operating I/L | -72.2M |
| Other Income/Expense | 7.2M |
| Interest Income | 7.8M |
| Pretax | -65.0M |
| Income Tax Expense | 72.2M |
| Net Income/Loss | -65.0M |
Viridian Therapeutics, Inc. is a biotechnology company specializing in the development of treatments for serious diseases. Their product portfolio includes VRDN-001, a humanized monoclonal anti-IGF-1R antibody in Phase 1/2 clinical trial for thyroid eye disease (TED); VRDN-002, an IGF-1R antibody in Phase 1 clinical trial; and VRDN-003, a therapeutic antibody targeting IGF-1R for TED treatment.
